• By David Grosby and Michael Borella

    Federal Circuit SealOn September 23, 2010, Eon filed suit against seventeen defendants in the District Court of the District of Delaware, alleging infringement of U.S. Patent No. 5,663,757.  During the case, the '757 patent went through two reexaminations.  The claims were amended in the first reexamination, and then confirmed valid as amended in the second reexamination.  After the reexaminations, the District Court granted summary judgment for the defendants, holding that all claims of the '757 patent were indefinite under 35 U.S.C. § 112 ¶ 6.

    Eon appealed.  On May 6, 2015, Chief Judge Prost of the Federal Circuit authored a decision clarifying the structure that patentees must disclose when using means-plus-function language in software patents.  Judges Newman and Bryson joined the opinion.

    The '757 patent is directed to software embodied in a "local subscriber data processing station that operates in tandem with a television to interconnect various interactive features of the television."  The software supports actions including "impulse purchase transactions with immediate payment, audience participation voting, and sorting television programs by theme."  Eon's infringement position centered on the defendants' alleged manufacture and use of a smartphone as a modern iteration of the '757 patent's local subscriber data processing station.

    Example claim terms that were held to be indefinite include "means under control of said replaceable software means for indicating acknowledging shipment of an order from a remote station" (claim 7); and "means controlled by replaceable software means operable with said operation control system for . . . reconfiguring the operation modes by adding or changing features and introducing new menus" (claims 1-6, 8-10).

    35 U.S.C. § 112 ¶ 6 states that if the patentee uses means-plus-function claim limitations, the claims will be construed to cover only the corresponding structure in the specification and the equivalents thereof.  It is well-settled that the "structure" for functions performed by software is the particular algorithm that performs these functions, rather than just the computer hardware that the software runs on.  In Aristocrat Techs. Austl. Pty Ltd. v. Int'l Game Tech., the Federal Circuit stated that "in cases involving a computer-implemented invention in which the inventor has invoked means-plus-function claiming, this court has consistently required that the structure disclosed in the specification be more than simply a general purpose computer or microprocessor."  There is one narrow exception to this rule, as explained in In re Katz Interactive Call Processing Patent Litigation, that a standard microprocessor can serve as a sufficient structure if the functions claimed "can be achieved by any general purpose computer without special programming."

    While Eon did not dispute that the '757 patent failed to disclose an algorithm, it did attempt to invoke the Katz exception.  But, the Federal Circuit had only analyzed this exception once, finding that it did not apply.  In Ergo Licensing, LLC v. CareFusion 303, Inc., the Court held that "[i]t is only in the rare circumstances where any general-purpose computer without any special programming can perform the function that an algorithm need not be disclosed."  Eon attempted to distinguish this case by claiming the '757 patent does not involve any "special programming" because it is relatively simple to implement.

    The Federal Circuit rejected this contention, stating a microprocessor can only serve as the structure if the claimed function is "coextensive" with a microprocessor itself.  The Court's three examples of coextensive functions are receiving data, storing data, and processing data.  The Court followed this reasoning to hold "[a] microprocessor or general purpose computer lends sufficient structure only to basic functions of a microprocessor . . . [a]ll other computer-implemented functions require disclose of an algorithm."

    The Court further stated that the purpose of § 112 ¶ 6 is to "limit . . . the scope of the claim to the particular structure disclosed, together with equivalents."  Eon contradicted this purpose, because claiming a general purpose computer or microprocessor does little or nothing to limit the ways in which the claimed functions can be implemented.  Thus, "when a patentee invokes means-plus-function claiming to recite a software function, it accedes to the reciprocal obligation of disclosing a sufficient algorithm as corresponding structure."

    Eon did not argue that the functions at issue are coextensive with those of a microprocessor, and its expert stated that a person skilled in the art would need to consult algorithms outside the specification to implement the claimed functions.  As a result, the Federal Circuit found that the mere disclosure of a microprocessor was insufficient for the '757 patent, and therefore the claims containing those terms are indefinite.

    This case reiterates that an algorithm must almost always be disclosed in the specification if the patentee is using means-plus-function claiming.  The narrow interpretation of the Katz exception will likely deter future parties from arguing that a general purpose computer or microprocessor serves as a sufficient structure for means-plus-function claim limitations.  However, the Court still left the boundaries of the Katz exception undefined.  Microprocessors are also capable of carrying out tasks such as adding, subtracting, multiplying, and dividing numbers, as well as moving data. Most microprocessors are also capable of floating point and even graphics operations.  Since the Court seems to have limited the Katz exception to only "basic functions" of a microprocessor, it remains unclear where the Court would draw the line between such a basic function and one that is more advanced.  Thus, the Court has left room — albeit not much — for parties using more advanced functions to argue that these functions are supported by standard microprocessors.

    Eon Corp. IP Holdings LLC v. AT&T Mobility LLC (Fed. Cir. 2015)
    Panel: Choef Judge Prost and Circuit Judges Newman and Bryson
    Opinion by Chief Judge Prost

  • By Josh Rich

    Goldman SachsIn 2009, Sergey Aleynikov was a computer programmer employed by Goldman Sachs to write high-frequency trading code.  He accepted an offer to join a new Chicago-based company, Teza Technologies.  Before he left Goldman Sachs, however, he sent portions of Goldman's high frequency trading code to a German website for his own future use.  After Goldman found out, it went to the FBI; Aleynikov was then arrested on a flight home from Chicago.  With that arrest began a circuitous journey through the U.S. legal system, governed by two different sovereigns and under two different legal regimes — neither one of which was ultimately found to cover his actions.

    Aleynikov was first tried in the U.S. District Court for the Southern District of New York on charges of violating the Federal Economic Espionage Act of 1996 ("EEA").[1]  At that time, the EEA's trade secret misappropriation provision established that "[w]hoever, with intent to convert a trade secret, that is related to or included in a product that is produced for or placed in interstate or foreign commerce, to the economic benefit of anyone other than the owner thereof, and intending or knowing that the offense will, injure any owner of that trade secret, knowingly . . . without authorization . . . downloads, uploads, . . . transmits, . . . or conveys such information" would be guilty of a criminal offense punishable with up to ten years in jail.  18 U.S.C. § 1832.  The parties disputed the application of the EEA to Aleynikov's behavior, Aleynikov's intent in uploading the code to the German website, and the importance of the uploaded code.  Eventually, however, the jury found Aleynikov guilty under the EEA.

    The U.S. Court of Appeals for the Second Circuit interpreted the EEA differently from the construction applied by the trial court.  It stressed that the EEA had been adopted as a response to the Supreme Court's decision that the National Stolen Property Act (18 U.S.C. § 2314) did not apply to purely intangible property, as found in Dowling v. U.S., 473 U.S. 207 (1985).  676 F.3d 71, 78 (2d Cir. 2012).  It then considered the differences in language between the economic espionage provision of the EEA (18 U.S.C. § 1831) and the trade secrets provision (18 U.S.C. § 1832).  The former did not require that the information be "related to or included in a product that is produced for or placed in interstate or foreign commerce," while the latter did.  Id. at 79.  Given the statutory language, the Second Circuit found that Goldman's was intended to remain confidential (and not be related to any product placed in interstate commerce).  Id. at 82.  It therefore overturned Aleynikov's Federal conviction.

    Remarkably, the Second Circuit's decision in the Federal Aleynikov case led to a change in the statute.  Although it cannot apply to the Aleynikov case (under both the Constitution's ex post facto clause and double jeopardy case law), § 1832 was amended to apply to any trade secret "that is related to a product or service used in or intended for use in interstate or foreign commerce."  Thus, in future cases, misappropriation of computer code that is intended to remain confidential, but used in relation to a service performed in interstate commerce, will be an offense under the EEA.

    Rather than returning Aleynikov's computer, other evidence, and passport, however, the U.S. Attorney's Office turned it all over to the New York County (Manhattan) prosecutor's office.  Ultimately, that evidence was ruled to be illegally transferred and inadmissible as evidence against Aleynikov.  The prosecutor's office decided to prosecute Aleynikov nonetheless.[2]  The state court prosecution proceeded under two statutes:  two counts of Unlawful Use of Secret Scientific Material (N.Y. Pen. L. 165.07) and one count of Unlawful Duplication of Computer Related Material (N.Y. Pen. L. 156.30).  The former statute provides, "A person is guilty of unlawful use of secret scientific material when, with intent to appropriate to himself or another the use of secret scientific material, and having no right to do so and no reasonable ground to believe that he has such right, he makes a tangible reproduction or representation of such secret scientific material by means of writing, photographing, drawing, mechanically or electronically reproducing or recording such secret scientific material."  Aleynikov challenged his State indictment on numerous grounds, ranging from double jeopardy to the high-frequency trading code not being "secret scientific material" to not having made a "tangible reproduction or representation."  The trial court judge rejected those arguments and allowed the case to go forward to trial.

    At trial in April 2015, Aleynikov argued that he had committed no crime, based both on his own lack of culpable intent and the technical language of the relevant statutes.  The jury returned with a split verdict:  guilty on one count of Unlawful Use of Secret Scientific Material, hung on the other count of Unlawful Use of Secret Scientific Material, and not guilty of Unlawful Duplication of Computer Related Material.

    On July 6, 2015, however, the trial court judge entered an order overturning the jury's finding of guilt on the count of Unlawful Use of Secret Scientific Material.  The judge asserted that he had no doubt that Aleynikov's actions were wrongful, but also found that prosecutors "did not prove he committed this particular obscure crime."  His findings were based on two deficiencies by the prosecutors:  first, that they failed to prove that Aleynikov made a "tangible reproduction or representation of such secret scientific material" and, second, that they failed to prove that Aleynikov intended to take much of the value of the high-frequency trading code.  Thus, the trial court found, the prosecutors had not proven all of the elements of the charged offense and Aleynikov could not be convicted.

    Under these circumstances, Sergey Aleynikov may finally be free from risk of criminal jeopardy from his actions at Goldman.  The Manhattan DA's office could still appeal, but it would be surprising to see an appellate court find that a virtual copy of information would constitute a "tangible reproduction," since the Supreme Court rejected that argument in Dowling.  But future defendants may not be so lucky:  the New York State Senate has already passed a bill that would criminalize the same sort of acts that Aleynikov undertook.  Thus, Aleynikov may end up with a unique position in legal history:  two vacated convictions based on the same acts and two laws changed because of those vacated jury decisions.


    [1] 18 U.S.C. §§ 1831-39.
    [2] The Manhattan DA’s office offered Aleynikov a plea bargain: if he pled guilty to one of the counts, they would agree to drop the other charges and seek no time beyond the one year he had already served awaiting trial on the Federal charges.  Aleynikov rejected the plea deal.

  • By Donald Zuhn

    NAILast month, the National Academy of Inventors (NAI) and the Intellectual Property Owners Association (IPO) published a list of the top 100 worldwide universities that received the most U.S. utility patents in 2014.  The NAI is a non-profit organization comprising U.S. and international universities, and governmental and non-profit research institutions, with over 3,000 individual inventor members.  The organization was founded in 2010 to recognize and encourage inventors, enhance the visibility of academic technology and innovation, and translate the inventions of its members to benefit society.  The joint effort by the NAI and IPO is based on data the IPO collects for its annual list of the top 300 organizations receiving U.S. patents (see "IPO Releases List of Top 300 Patent Holders for 2014").  The top 20 universities on the NAI/IPO listing are as follows (click on table to expand):

    Top 20 University Patents
    The complete list of 100 universities can be found here.

    For additional information regarding this and other related topics, please see:

    • "IPO Releases List of Top 300 Patent Holders for 2014," July 1, 2015
    • "IPO Names Top 100 Patenting Universities," July 24, 2014
    • "NAI & IPO Release List of Top 100 Universities Receiving Patents in 2012," January 7, 2014
    • "IPO Releases List of Top 300 Patent Holders for 2013," July 7, 2014
    • "Brookings Paper Calls for Technology Transfer Model Based on University Start-ups," December 12, 2013
    • "IPO Releases List of Top 300 Patent Holders for 2012," June 24, 2013
    • "Another Look at IPO Top 300 and Life Sciences Top 53," June 11, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2011," June 7, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2010," June 30, 2011
    • "IPO Releases List of Top 300 Patent Holders for 2009," May 26, 2010
    • "IPO Releases List of Top 300 Patent Holders for 2008," May 14, 2009
    • "IPO Releases List of Top 300 Patent Holders," May 22, 2008
    • "IPO Posts List of Top 300 Patent Holders," April 20, 2007

  • CalendarJuly 8-10, 2015 – Fundamentals of Patent Prosecution 2015: A Boot Camp for Claim Drafting & Amendment Writing (Practising Law Institute) – San Francisco, CA

    July 9, 2015 – "Leveraging Post-Grant Patent Proceedings Before the PTAB — Best Practices for Patentees and Third Parties in Inter Partes Review, Post-Grant Review and Covered Business Method Patent Challenges" (Strafford) – 1:00 to 2:30 pm (EDT)

    July 14, 2015 – Patent Quality Chat webinar series – Face-to-face Examiner Interviews: A Demonstration of USPTO Tools – noon to 1:00 pm (EDT)

    July 16-17, 2015 - "Advanced Patent Prosecution Seminar 2015: Claim Drafting & Amendment Writing" (Practising Law Institute) – New York, NY

    July 20-21, 2015 – Patent Cooperation Treaty Seminar (American Intellectual Property Law Association) – San Francisco, CA

    July 23, 2015 – "Section 103 and Non-Obviousness Post-AIA — Navigating Timing Changes, Federal Court Treatment, and Secondary Considerations to Meet Patent Validity Requirements" (Strafford) – 1:00 to 2:30 pm (EDT)

    July 23-24, 2015 – Patent Cooperation Treaty Seminar (American Intellectual Property Law Association) – Alexandria, VA

    August 10-11, 2015 – "Advanced Patent Prosecution Seminar 2015: Claim Drafting & Amendment Writing" (Practising Law Institute) – San Francisco, CA

    August 11, 2015 – Patent Quality Chat webinar series – Measuring Patent Quality – noon to 1:00 pm (EDT)

    August 12-14, 2015 – Advanced Patent Law Seminar (Chisum Patent Academy) – Seattle, WA

    September 10-11, 2015 - "Advanced Patent Prosecution Seminar 2015: Claim Drafting & Amendment Writing" (Practising Law Institute) – Chicago, IL

    ***Patent Docs is a media partner of this conference or CLE

  • PLI #1Practising Law Institute (PLI) will be holding a two-day seminar entitled: "Advanced Patent Prosecution Seminar 2015: Claim Drafting & Amendment Writing" on July 16-17, 2015 in New York, NY, on August 10-11, 2015 in San Francisco, CA, and on September 10-11, 2015 in Chicago, IL.  Patent Docs authors Donald Zuhn and Kevin Noonan will be presenting at the Chicago seminar.

    At the New York and Chicago seminars, PLI's faculty will offer presentations on the following topics:

    • Ethics in the PTO
    • Concurrent Sessions I:  Advanced Specification Drafting Issues — all concurrent sessions and workshops will provide lectures specific to four different technologies:  biotechnology, chemical/pharmaceutical, electromechanical, and electronics/computers
    • Concurrent Sessions II:  Advanced Claim Drafting Issues
    • Concurrent Seminars I:  Advanced Claim Drafting
    • Patent Eligible Subject Matter After Myriad, Alice and the PTO Interim Guidance
    • Lessons Learned from Two Years of Post-Grant Proceedings
    • Concurrent Sessions III: Advanced Patent Prosecution Issues
    • Concurrent Seminars II:  Advanced Amendment Drafting
    • Roundtable Discussions and Wrap Up.

    At the San Francisco seminar, presentations will be offered on the following topics:

    • Ethics for Patent Prosecutors
    • The New 35 USC §102
    • Advanced Claim Drafting Issues — class to split into technology groups, including Electromechanical/Mechanical, Electronics/Computers, and Life Sciences (Biotechnology, Chemical/Pharmaceutical)
    • Claim Drafting Seminars — class to split into technology groups
    • Advanced Issues for Written Description — class to split into technology groups
    • Countering the Obviousness Rejection
    • Post Final Practice
    • The Litigation Perspective on Patent Prosecution
    • Amendment Seminars — class to split into technology groups

    A complete program schedule, including descriptions of the presentations and a list of speakers for each seminar can be found here.

    The registration fee for each conference is $1,795.  Those interested in registering for the conference can do so here.

  • Strafford #1Strafford will be offering a webinar/teleconference entitled "Section 103 and Non-Obviousness Post-AIA — Navigating Timing Changes, Federal Court Treatment, and Secondary Considerations to Meet Patent Validity Requirements" on July 23, 2015 from 1:00 to 2:30 pm (EDT).  Thomas L. Irving and Erika H. Arner of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel regarding the impact of the Leahy-Smith America Invents Act (AIA) on Section 103 and non-obviousness, and offer best practices for meeting the non-obviousness requirement for patent validity.  The webinar will review the following questions:

    • How has the AIA impacted the determination of obviousness?
    • How has the Federal Circuit treated the issue of non-obviousness?
    • How has PTAB treated obviousness issues?
    • What practices should counsel employ in order to meet the non-obviousness requirement?

    The registration fee for the webinar is $297 ($362 for registration and CLE processing).  Those interested in registering for the webinar, can do so here.

  •     By Paul Cole* —

    Ariosa DiagnosticsThe June 12, 2015 decision of the Federal Circuit in the above case has been discussed by Kevin Noonan in his posting of 22 June, but it is believed that the factual and legal background could benefit from further discussion.

    It is convenient to consider claims 1 and 2 of US Patent No. 6,258,540 together since PCR is the technique exemplified and both claims 1 and 2 were held not to be patent eligible.

    The kernel of the opinion of Judge Reyna is contained in the two passages set out below:

    It is undisputed that the existence of cffDNA in maternal blood is a natural phenomenon.  Sequenom does not contend that Drs. Lo and Wainscoat created or altered any of the genetic information encoded in the cffDNA, and it is undisputed that the location of the nucleic acids existed in nature before Drs. Lo and Wainscoat found them.  The method ends with paternally inherited cffDNA, which is also a natural phenomenon.  The method therefore begins and ends with a natural phenomenon.  Thus, the claims are directed to matter that is naturally occurring.

    Like the patentee in Mayo, Sequenom contends that the claimed methods are patent eligible applications of a natural phenomenon, specifically a method for detecting paternally inherited cffDNA. Using methods like PCR to amplify and detect cffDNA was well-understood, routine, and conventional activity in 1997.  The method at issue here amounts to a general instruction to doctors to apply routine, conventional techniques when seeking to detect cffDNA.  Because the method steps were well-understood, conventional and routine, the method of detecting paternally inherited cffDNA is not new and useful.

    It is useful to consider the steps of the claimed method against these statements to determine the extent to which they can legitimately be held to fall within the natural phenomenon exclusion.  Detail in addition to the express wording of the claim is believed to indicate what would be implicit to a skilled reader.

    The first step requires the use of a maternal serum or plasma sample from a pregnant female.  In Example 1, 10μl of centrifuged and heated plasma or serum are placed into a 0.5 ml Eppendorf tube.  While the presence of cffDNA in the maternal serum or plasma is a natural phenomenon, the decision to make use of the serum or plasma sample for amplification and detection is arguably a step towards an application of that phenomenon.

    The second step involves addition of pair of primers to the blood or serum sample.  In Example 1 of the patent in issue these are Y1.7 andY1.8 which are specific for the Y-chromosome which is passed only from father to son and determines the sex of the fetus.  Those primers enable amplification of a sequence of the Y-chromosome of length 198 base pairs.  The experimental details in Example 1 are less than complete, but comparison with Example 2 shows that ~300 nM of each amplification probe would have been added and 200μM each of dATP, dCTP, dGTP and dUTP to provide the monomeric nucleotides needed for polymerisation, together with polymerization enzyme and incidental materials.  The serum or plasma samples were then subjected to 60 cycles of polymerase chain reaction in a PCR machine, 30-40 cycles being generally regarded as sufficient for the reaction to go to completion.  As explained at page 3 of the slip opinion, amplifying cffDNA results in a single copy, or a few copies, of a piece of cffDNA being exponentially multiplied across several orders of magnitude, generating thousands to millions of copies of that particular DNA sequence to reach detectable levels.  If a sample originally contains one or more parentally-derived Y-chromosomes, then after amplification thousands or millions of copies of the selected 198 bp short sequence are present in it.

    The product of the second step could therefore most appropriately be described as a composition of matter which is for that reason inherently within the realm of patent-eligibility, said composition comprising the blood or serum of the sample, the naturally occurring cffDNA, thousands to millions of copies of the the Y-chromosome short sequence and residual primer, nucleotides, enzyme and other starting materials.  Even if concentration is focused on the short sequences to the exclusion of other relevant process and composition of matter features, the short sequence copies are a wholly artificial creation, being the result of the synthetic chain reaction and to describe them as a natural product gives rise to an error, on the figures of the slip opinion, of 103-106 which is on any view an exuberant margin.  They have new utility compared to the original blood or serum sample insofar as they are present at levels that are detectable in subsequent test procedures whereas the original cffDNA is not.

    Furthermore in equating the selected and amplified short sequences with a natural product, the Court is implicitly disregarding long-established precedents such as Parke-Davis & Co. v. H. K. Mulford Co (adrenalin), Kuehmsted v. Farbenfabriken of Elberfeld Co. (aspirin) and Merck & Co. v. Olin Mathieson Chemical Corp (Vitamin B12) which show that an isolated or purified natural product having new utility is patent-eligible.  By the same logic, the amplified short sequences are a new and different product having new utility in that they have been brought to detectable levels and cannot be equated simply with the corresponding region of the Y-chromosome as a natural product.

    The third step involves detecting the presence of the paternally inherited nucleic acid, and although specified at a high degree of generality is not unduly broad having regard to the range of tests that can be performed.  In Example 1, the mere presence of a Y-positive signal distinguishes a male fetus from a female fetus.  In Example 2, quantitative PCR is used as a screening marker for aneupoloid pregnancies e.g. Downs syndrome, Example 3 describes tests for RhD, Example 4 describes tests for pre-eclampsia and Example 5 provides data showing the very high concentration of fetal DNA in serum or plasma compared to the cellular fraction of maternal blood.

    Prometheus requires the claim to be considered not merely as an isolated aggregation of features but as an ordered combination.  If that is done, the new result emerges of a test of high sensitivity for a range of medical conditions that can be applied early in pregnancy and avoiding the risks to the fetus inherent in amniocentesis and that starts from a new and hitherto overlooked starting material and that, in the words of Judge Reyna "revolutionised medical care."  The question in Prometheus was whether the described processes added enough, and it is submitted that the benefits achieved should not have been dismissed as adding nothing of significance.

    The proposition that because the method steps were well-understood, conventional and routine, the method of detecting paternally inherited cffDNA is not new and useful verges on the incomprehensible.  Essentially the same claim was examined by the EPO Appeal Board T 0146/07 ISIS/Prenatal diagnosis.  The closest prior art was a paper from one of the inventors, Dr Lo.  That paper describes a method for the detection of foetal RhD sequences in peripheral blood of sensitized RhD-negative pregnant women.  In the earlier method described, antecubital venous blood was collected from pregnant women and DNA was extracted from the buffy coat fraction, i.e., peripheral blood mononuclear cells (PBMC) isolated from maternal peripheral blood.  Foetal RhD sequences were detected by PCR using specific primers.  The method therefore differed from that now claimed in that the presence of nucleic acid of foetal origin was detected in buffy coat cells rather than in maternal serum or plasma.  As explained in the patent in issue, it was surprisingly found that foetal DNA is enriched in maternal plasma or serum compared to the amount present in the cellular fraction.  The Opposition Division found that a skilled person starting from the cited document and confronted with the problem of providing a more sensitive method for detecting foetal blood cells would not have derived the solution claimed.  In affirming this finding, the Appeal Board held that even of the technical problem were reformulated to the lesser task of finding an alternative source of foetal nucleic acid a skilled person starting from Dr Lo's paper would not have been motivated to consider serum or plasma samples.  Lack of industrial applicability was not a ground of opposition, but nevertheless it is disturbing that subject matter held inventive by the EPO should be summarily dismissed as ineligible in the U.S. under §101.

    The steps quoted from the Prometheus opinion recur in Alice and to that extent may reflect a settled view within the Supreme Court.  However, it is submitted that it is inappropriate to select specific passages from these opinions without taking into account the caution with which they were originally expressed, and the warning at the end of the Prometheus opinion that a new protective rule that seems to suit the needs of one field might produce unforeseen results in another.  It is difficult to avoid the conclusion that in Ariosa the Court is extending the second part of the two-part Prometheus test beyond the original intention of the Supreme Court and has fallen into the trap of making its findings of fact to fit the earlier opinions on which it wished to rely, rather than straightforwardly finding the objective facts and then applying the appropriate jurisprudence to them.

    * Mr. Cole is a European Patent Attorney and Partner with Lucas & Co. in Warlingham, Surrey, UK and Professor of IP Law at Bournemouth University.

  • Life Sciences Top 55

    By Donald Zuhn —

    IPO #2Last week, the Intellectual Property Owners Association (IPO) announced the release of its 32nd annual list of the top 300 organizations receiving U.S. patents (see "Top 300 Organizations Granted U.S. Patents in 2014").  Patent Docs Readers may recall that the U.S. Patent and Trademark Office stopped releasing its annual list of top patent recipients in 2006 in order to "discourag[e] any perception that we believe more is better."

    The IPO compiled its list by counting the number of utility patents granted during 2014 that listed an organization or a subsidiary as the owner on the printed patent.  The IPO notes that if an assignment to an organization or its subsidiary was recorded after the patent was printed, the patent was not counted, and further, that patents that were granted to two or more organizations jointly were attributed to the organization listed first on the patent.  The IPO also noted that 300,678 patents were issued in 2014, which was an increase from the 277,835 patents that issued in 2013.  The top fifteen companies on the IPO Top 300 are listed below (click on table to expand):

    2014 Top 15
    Falling out of the Top 15 in 2013 were Fujitsu Ltd. and Siemens AG, which dropped to 16th and 21st, respectively.  Replacing those companies in the Top 15 were Intel Corp. and AT&T Corp.

    As in past years, Patent Docs used the IPO's list of top patent holders to compile a list of the top "life sciences" companies and organizations receiving U.S. patents in 2014.  In the past seven years, the number of life sciences companies and organizations making the list has gone from 51 in 2006 to 47 in 2007, 43 in 2008, 47 in 2009, 56 in 2010, 53 in 2011, 50 in 2012, 49 in 2013, and 55 last year.  Each organization's IPO top 300 ranking for 2014 is indicated in the "2014 IPO Rank" column; the IPO top 300 ranking for 2013 (if available) is indicated in the "2013 IPO Rank" column; and the change in number of patents from 2013 is indicated in "% Change from 2013."  The Life Sciences Top 55 is listed below (click on table to expand):

    2014 LS Top 55
    Life sciences companies and organizations that failed to make the IPO top 300 in 2014 after making it in 2013 included Covidien AG (#49 on the IPO top 300 for 2013), Pacesetter, Inc. (271), Life Technologies Corp. (293), and National Taiwan University (296).  UPDATE: A Patent Docs reader reminded that in January 2015, Medtronic, Inc. announced that it had completed the acquisition of Covidien plc.  Medtronic moved from #42 on the IPO Top 300 for 2013 to #17 in 2014.

    Please note that some of the companies and organizations listed above may be involved in work outside the life sciences sector, and therefore, a portion of the patents granted to these companies and organizations may be directed to other than life sciences-related inventions.  In addition, our list includes medical device companies.

    For additional information regarding this topic, please see:

    • "IPO Releases List of Top 300 Patent Holders for 2013," July 7, 2014
    • "IPO Releases List of Top 300 Patent Holders for 2012," June 24, 2013
    • "Another Look at IPO Top 300 and Life Sciences Top 53," June 11, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2011," June 7, 2012
    • "IPO Releases List of Top 300 Patent Holders for 2010," June 30, 2011
    • "IPO Releases List of Top 300 Patent Holders for 2009," May 26, 2010
    • "IPO Releases List of Top 300 Patent Holders for 2008," May 14, 2009
    • "IPO Releases List of Top 300 Patent Holders," May 22, 2008
    • "IPO Posts List of Top 300 Patent Holders," April 20, 2007

  • By Kevin E. Noonan

    Court of Appeals - 3d CircuitEver since the Supreme Court's decision in FTC v. Actavis in 2013, courts (predominantly district courts) have grappled with the scope of the decision.  It was evident that the presence of a large cash payment from the innovator (branded) drug company to the generic challenger as part of a "reverse payment" settlement agreement in ANDA litigation was enough to provoke a "rule of reason" antitrust analysis according to the rubrics set forth in Justice Breyer's opinion.  The more difficult question was whether other forms of consideration could lead to the same result.  A specific type of such "other" compensation from branded plaintiff to generic defendant was a promise by the branded drug maker not to market a so-called "authorized generic" form of the branded drug (i.e., a generic form of the drug marketed by the branded company), especially during the 180-day exclusivity period that a successful generic challenger received for being the "first filer" of an ANDA.  District courts have split on the issue, as shown in this non-exhaustive list:

    In re Nexium (Esomeprazole) Antitrust Litig., 968 F. Supp. 2d 367 (D. Mass. 2013) (no authorized generic; mixed decision on state law)

    In re Wellbutrin XL Antitrust Litig., No. 08cv-2431, DKT No. 534 (E.D. Pa. Jan. 17, 2014) (no authorized generic triggered rule of reason analysis)

    In re Lipitor Antitrust Litigation, 2014 WL 282755 (D.N.J. Jan. 24, 2014) (not limited to cash payments but rather the total value of whatever is transferred from the brand to the generic) (see "Judge Sheridan Dismisses More Plaintiffs in Lipitor Antitrust Case")

    In re Loestrin 24 FE Antitrust Litig., MDL No. 13-2472-S, DKT No. 116 (D.R.I. Sept. 4, 2014) (money means money)

    In re Niapsan Antitrust Litigation, 2014 U.S. Dist. LEXIS 124818 (E.D. Pa. Sept. 5, 2014) (monetary terms not required)

    In re Lipitor Antitrust Litigation, 3:12-cv-02389 (PGS) (Sept 12, 2014) (antitrust allegations dismissed on the pleadings)

    In re Effexor Antitrust Litigation, 11:5479 (PGS) (Oct. 6, 2014) (accord with Lipitor decision)

    And in the District Court decision here (In re Lamictal Direct Purchaser Antitrust Litig. 18 F. Supp. 3d 560, 561 (D.N.J. 2014), the Court held that the Actavis decision was limited to instances where there was a cash payment from the brand company to the generic challenger.

    A more definitive answer (for now) comes from the Third Circuit's decision issued last Friday in the appeal from the Lamictal case.  And the answer is that Actavis is not limited to reverse payment settlement agreements having a cash transfer to the generic, but can also include other types of consideration, in particular a promise from the brand not to market an authorized generic during the 180-day exclusivity period (see opinion).

    Teva #1The Court's rationale (from a panel having no members in common with the panel that decided the K-Dur appeal that prompted Supreme Court review of reverse payment settlement agreements) illustrates the consequences of Justice Breyer's opinion.  The case involved Teva's generic versions of Glaxo-SmithKline's (GSK) Lamictal® (lamotrigine) drug for epilepsy and bipolar disorder; the patent on the drug expired in 2008.  The court considered the antitrust question in view of an earlier (January 2005) decision that claim 1 of the patent was invalid as anticipated by prior art.  The settlement agreement contained three provisions where, in exchange for settling ANDA litigation asserting challenges to GSK's patents, Teva would be allowed to market generic lamotrigine chewables (an annual $50 million market), 37 months before patent expiry and tablets (an annual $2 billion market), at the end of the patent's term.  (The difference in the times of entry and the sizes of the markets played a role in the Court rejecting the argument that the agreement was precompetitive due to early market entry of the generic drug.)  In particular, the agreement contained a provision that Teva's generic tablets and chewables would not face competition from GSK's own "authorized generic."  Plaintiffs here are a class of "direct purchasers" (i.e., wholesale drug sellers).

    GlaxoSmithKline - GSKThe Third Circuit panel vacated the District Court's grant of a motion to dismiss for failure to state a claim under Fed. R. Civ. Pro. 12(b)(6) and remanded.  The Court rejected the argument that the Actavis decision should be limited to cash payments.  Rather, the Court considered the benefit to generic challenger Teva arising from branded drug maker Glaxo SmithKline's agreement not to market an "authorized generic" version of lamotrigine during Teva's 180-day exclusivity period as part of a settlement agreement ending ANDA litigation between the companies.  In making this determination the Court recognized that although there was no frank money payment from GSK to Teva, the complaint recited sufficient allegations that the Court should apply the "rule of reason" to plaintiffs' challenge to the agreement for violating Sections 1 and 2 of the Sherman Act.  Important in its analysis was that GSK would be permitting Teva to be the sole generic entering a $2 billion market for Lamictal® capsules and that the value to Teva was "an unexplained large transfer of value from the patent holder to the alleged infringer" that implicated the rationale provided by the Supreme Court in its Actavis decision for subjecting the agreement to antitrust scrutiny under the rule of reason.

    The Court specifically held that the "no-authorized generic" portion of the agreement "may represent an unusual, unexplained reverse transfer of considerable value from the patentee to the alleged infringer and may therefore give rise to the inference that it is a payment to eliminate the risk of competition" which were the types of agreements (albeit in the context of cash payments) that Actavis held were subject to antitrust scrutiny.

    The Court's prejudices (consistent with the general anti-patent consensus that has arisen in this century) are reflected in how the Court begins it analysis, stating that patents are "the exception to the general rule against monopolies" and that "Patent Clause itself reflects a balance between the need to encourage innovation and the avoidance of monopolies which stifle competition without any concomitant advance in the 'Progress of Science and useful Arts,'" citing Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 146 (1989) (perhaps the first instance of the Court enunciating Justice Breyer's "Goldilocks" view of this need for balance in patenting).  (It is illustrative that the Court cites in support of this balancing idea a passage from Areeda and Hovencamp's treatise, Antitrust Law, that states "Patent law . . . serves the interests of consumers by protecting invention against prompt imitation in order to encourage more innovation than would otherwise occur.")  And the panel cited Justice Breyer's Actavis decision, specifically the cases cited therein (and rebutted by the Chief Justice in his dissent) to support these prejudices.

    The panel also recognizes that the Court identified reverse payment settlement agreements to be outside the norm because the included large cash settlements from the patentee to the accused infringer (hence the term "reverse payment") and that such settlement terms were extremely unusual and uncommon outside ANDA litigation.  Nevertheless, the panel held that "no authorized generic" agreements could fall within the province of the "five sets of considerations" set forth in Justice Breyer's opinion depending on the value to the generic challenger in having the branded drug maker forswear from marketing its own generic version of a branded drug.  Here, the Court reasoned:

    It seems to us that no-AG agreements are likely to present the same types of problems as reverse payments of cash.  The no-AG agreement here may be of great monetary value to Teva as the first-filing generic.  In Actavis, the Supreme Court recognized generally that the 180-day exclusivity period is "possibly 'worth several hundred million dollars,'" and may be where the bulk of the first-filer's profits lie.

    Citing "evidence" from amicus briefs, the Court then states that:

    There are also plausible indicia that this pattern held true here: the Amici States point out that "[p]ublic records show that generic sales of Lamictal in 2008 were some 671 million dollars," so the no-AG agreement "was clearly worth millions of dollars, if not hundreds of millions of dollars[,] to the generic."

    The FTC also weighed in (to the extent that whatever expertise the Commission has provided support for the Court's opinion), wherein:

    The FTC suggests, using sales of the drug Paxil as a yardstick, that GSK's no-AG agreement would have been worth hundreds of millions of dollars to Teva. [emphasis added]

    (The opinion "explains" in a footnote how "sales of Paxil" can be used as a yardstick for Lamictal sales; the only relevant statistic is the similar market value of Paxil compared with Lamictal immediately prior to generic competition.)

    The panel also considered abstaining from marketing an authorized generic to be equivalent to "transfer[ring] the profits the patentee would have made from its authorized generic to the settling generic — plus potentially more, in the form of higher prices, because there will now be a generic monopoly instead of a generic duopoly."  And this is how the Court makes the equation from frank cash payments to the no authorized generic provisions of this settlement agreement:

    Absent a no-AG promise, launching an authorized generic would seem to be economically rational for the brand.  For this reason, the fact that the brand promises not to launch an authorized generic (thereby giving up considerable value to the settling generic) makes the settlement something more than just an agreed-upon early entry: it "may instead provide strong evidence that the patentee seeks to induce the generic challenger to abandon its claim with a share of its monopoly profits that would otherwise be lost in the competitive market." [citing Actavis]

    The Court also rejected defendants' argument that the "no authorized generic" portion of the agreement was an exclusive license, inter alia because (in a footnote) the panel stated that the agreement was not an exclusive license and in the body of the opinion opined that licensing could not be used solely for anticompetitive effect.

    The result of this decision is that, at least in the Third Circuit, the scope of agreements subject to the rule of reason (or at least not subject to being dismissed for failure to state a claim) includes those having "no authorized generics" provisions in addition to agreements involving cash payments to generic challengers from branded drug makers.  This upsets several earlier decisions in this circuit, and it remains to be seen whether other circuits accept the panel's reasoning in considering this question.

  • By Eddie Obissi and Michael Borella

    Note: This coverage of a district court case from last year provides an overview of the patented invention, as well as the decision currently being appealed to the Federal Circuit.  In a subsequent article, we will review the parties' briefs.

    District Court for the District of DelawareOn November 21, 2012, McRo, Inc., doing business as Planet Blue, initially commenced action in the District Court of the District of Delaware against a number of defendants.  Planet Blue alleged infringement of U.S. Patent Nos. 6,307,576 and 6,611,278, the latter a continuation of the former.  More defendants were added in subsequent suits, and the cases were consolidated and transferred to the Central District of California.  The defendants — now numbering 23 — jointly filed a motion for judgment on the pleadings based on 35 U.S.C. § 101.  On September 22, 2014, District Court Judge Wu ruled for the defendants on the motion.  Planet Blue's appeal to the Federal Circuit is currently pending.

    Ever since the Supreme Court's decision in Alice Corp. v. CLS. Bank Int'l, the federal courts and the U.S. Patent and Trademark Office have struggled to apply the two-step subject matter eligibility test therein.  Last year, Federal Circuit case law refined the boundaries of § 101 to some extent.  In Ultramercial v. Hulu, the Court reiterated that a disembodied method merely using general-purpose technology (i.e., the Internet) fails to meet the requirements of § 101, while in DDR Holdings  v. Hotels.com, the Court stated that a claimed invention that is necessarily rooted in computer technology (e.g., one that changes the technology itself rather than just using it) is patent-eligible.

    While distinguishable, the line between Ultramercial and DDR Holdings is fine.  Patentee and defendant arguments often boil down to whether the claims under dispute are more or less like those of one case or the other.  The present case is being viewed as an opportunity for the Federal Circuit to clarify its interpretation of § 101.  Thus, it is helpful to consider the proceedings in the District Court.

    Judge Wu's patent-eligibility analysis focused on claim 1 of the '576 patent, which recites:

    A method for automatically animating lip synchronization and facial expression of three-dimensional characters comprising:
        obtaining a first set of rules that define output morph weight set stream as a function of phoneme sequence and time of said phoneme sequence;
        obtaining a timed data file of phonemes having a plurality of sub-sequences;
        generating an intermediate stream of output morph weight sets and a plurality of transition parameters between two adjacent morph weight sets by evaluating said plurality of sub-sequences against said first set of rules;
        generating a final stream of output morph weight sets at a desired frame rate from said intermediate stream of output morph weight sets and said plurality of transition parameters; and
        applying said final stream of output morph weight sets to a sequence of animated characters to produce lip synchronization and facial expression control of said animated characters.

    The claimed invention relates to generating automated lip-synchronization and associated facial expression for 3D animated characters.  The prior art generally encompassed a "morph target" approach, where the 3D character's facial orientation would be represented by a vector of values ("morph weights") associated with various vertices disposed across the character's face.  The facial orientation would change based on differences in vertex values from those assigned to the face at rest.  To animate the character's speech, for example, one would manually insert the appropriate morph weights at critical times (in "keyframes") in the associated recording, and a computer program would interpolate between the facial expressions to provide a visual impression of different sounds being uttered.  This process, however, was inefficient and tedious, since many morph targets would need to be manually set in order to make the animated facial expression accurately match the recording.  Planet Blue's contribution was intended to automate this process by feeding time-aligned phonetic transcripts into a computer, and setting rules for how to apply various morph targets to manipulate the 3D character's facial expressions based on this input.

    The defendants argued that, under the post-Alice § 101 framework, the claims of the patents were ineligible because they simply "set forth the previously-known animation method as a series of mathematical steps, and instruct the user to perform those steps on a computer."  To evaluate this argument, Judge Wu focused on interpreting the Alice ruling.

    The first step in the Alice test is whether the claims incorporate a patent-ineligible concept (e.g., an abstract idea, law of nature, or natural phenomenon).  The second step is whether the claims also supply an 'inventive concept' that renders the claims patentable, despite the inclusion of the patent-ineligible concept.  According to this test, an 'inventive concept' is "an element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself."  In considering Alice, Judge Wu observed that, "so far, the two-part test for identifying an abstract idea appears to be of limited utility, while comparisons to previously adjudicated patents — or more precisely, to past cases' characterizations of those patents — have done the heavy lifting."  Despite criticizing the Alice opinion as setting forth an "I know it when I see it" test, he shrugged off the implications thereof and noted "[i]n any event, the Supreme Court has spoken, and § 101 now plays an important limiting role."

    Beginning his substantive analysis, Judge Wu wrote a section entitled "The Claims, In Isolation, Appear Tangible and Specific."  He observed that the claims did not appear to preempt all uses of rules for 3-D lip synchronization.  He further noted that the claims did not preempt the prior art methods of computer-assisted lip synchronization.  Thus, Judge Wu admitted that "[a]t first blush, it is therefore difficult to see how the claims might implicate the basic underlying concern that these patents tie up too much future use of any abstract idea they apply."

    After making these remarks that seemed encouraging for the patentee, Judge Wu determined that "it is not enough to view the claims in isolation."  Rather, he carried out an analysis that is reminiscent of the abstraction-filtration-comparison test for substantial similarity of computer programs described in the copyright case of Computer Associates International, Inc. v. Altai, Inc.  First, he decided that in § 101 analyses, it is appropriate to remove "conventional activity."  Thus, if the elements of the claims not covered by the prior art are directed to an abstract idea, the invention can be patent-ineligible under § 101.  Such a method of claim evaluation has been called a "point of novelty" analysis.

    Applying Alice to the claims, Judge Wu found the point of novelty of Planet Blue's claims to be "the idea of using rules, including timing rules, to automate the process of generating keyframes."  Working against Planet Blue throughout this analysis was its own admitted prior art.  Judge Wu was able to form a claim chart mapping most of the claim elements to features described as prior art in the '576 patent.  After making this comparison, Judge Wu characterized the point of novelty as simply using rules, rather than people, to set the morph targets in achieving the same result of 3D lip synchronization.

    He noted that, in claiming the novel portion of the invention, the patentees described these concepts "at the highest level of generality."  The invention did not specify the exact rules to be applied in generating the morph targets, and stipulated that the user should set them to her preference.  Judge Wu found that, because the patent purported to claim all such rules but described just one set of example rules, the claims merely state an abstract idea and tell one to apply it.  Consequently, the claims do not supply an inventive concept under Alice.  Though his reasoning is couched in terms used by the Supreme Court in Alice, it simply masks Judge Wu's true argument — that Planet Blue claimed its invention too broadly (Judge Wu's focus on the specification's level of descriptive detail for the determination of an 'inventive concept' is similar to the approach that we have recently seen in Internet Patents Corp. v. Active Network, Inc.).

    Thus, despite his initial observation that the claims did not seem unduly preemptive, Judge Wu found that the claimed invention preempted "the field of automatic lip synchronization for computer-generated 3D animation . . . using a rules-based morph target approach."  And also despite stating that "the [§ 112] written description requirement guards against claims that merely recite a description of the problem to be solved while claiming all solutions to it" he made this finding under the auspices of § 101.  In short, Judge Wu used patent-eligibility to make a written description and enablement argument, and justified it by saying that the claims preempted what is indisputably a very narrow field.

    Nor did inventiveness make the claims patentable.  Not unlike the Federal Circuit in Ultramercial, Judge Wu found that novelty does not necessarily preclude a finding of invalidity under § 101.  Evidence that one of the defendants called the invention "revolutionary" similarly failed to sway the decision.  Judge Wu declared that "for purposes of the § 101 inquiry, which is different from the § 103 inquiry, the revolutionary nature of an abstract idea does not weigh in favor of patentability."  To make this point, he cited Mayo Collaborative Services v. Prometheus Laboratories, Inc., where the Supreme Court gave Einstein's mass-energy equivalence in his Theory of Special Relativity as an example of something that would not be patentable under § 101.

    Judge Wu's application of the Alice framework to the patents in dispute has been subject to criticism.  Perhaps the most comprehensive overview of this case is District Court Judge Pfaelzer's analysis in California Institute of Technology v. Hughes Communications.  Judge Pfaelzer offered three substantive critiques of Judge Wu's application of the Alice framework.

    First, she asserted that Diamond v. Diehr represented an affirmative step by the Supreme Court to reject the point of novelty approach engendered in its previous decision in Parker v. Flook.  She noted that neither Bilski, nor, Mayo, nor Alice, nor any relevant precedent had revived the analysis in § 101 decisions.  Therefore it was inappropriate for Judge Wu to "dissect . . . a claim into old and new elements" when evaluating an abstract idea under the Alice framework.

    Second, Judge Pfaelzer found that Judge Wu had conflated step one and step two of the framework.  By filtering the claim elements before determining that an abstract idea existed, he had ignored that Mayo and Alice dictate that an abstract idea be determined before evaluating whether the claims add "something more."  This point also makes clear that Judge Wu's prior assertion that using step two to find a patent valid means that "there was a categorization error . . . in step one," is not the case.  Rather, Judge Pfaelzer's point elucidates the notion accepted by the Supreme Court in Alice and Mayo that all inventions, to some degree, encompass abstract ideas.

    Indeed, Alice, Mayo, and Diehr all require that claims should be considered "as a whole" or as "an ordered combination."  Step two of the Alice test allows conventional aspects of a claim to be ignored during the 'something more' determination.  But there is no authority for such piecemeal analysis during step one.

    Third, Judge Pfaelzer attacked the functional implications of Judge Wu's approach.  Judge Pfaelzer went to some lengths to establish that software is still patentable after Alice, not only because of congressional recognition of such patents in the America Invents Act, but also because of express language in the Supreme Court's analysis in Alice.  However, she found that "it is difficult to imagine any software patent that survives under [Planet Blue's] approach."  Thus, she declared that Judge Wu's § 101 analysis of the invention "appears to reach the wrong conclusion."

    Nearly all judges applying the Alice framework have noted that § 101 is a murky area of law, especially in the context of software inventions.  That being said, Judge Wu used a rationale based on a partial prior art and written description analysis to invalidate the patent under § 101.  This point of novelty approach to patentability is subjective and has led to a counter-intuitive result — an innovative, "revolutionary" patent being struck down as "too broad," even when there is no prior art of record that discloses or suggests the claimed invention as a whole.

    But even if the Federal Circuit disagrees with Judge Wu's analysis, it may come to the same ultimate conclusion.  Based on Alice, Mayo, Ultramercial, and DDR, one can craft reasonable arguments that could find Planet Blue's patent valid or invalid under § 101.  Unfortunately, this case boils down to whether the Federal Circuit truly knows a patent-eligible claim when they see it.